See editorial on page 374; see similar article on page 360. E pidemiologic studies of achalasia are essential in providing insight into this rare disease, but performing accurate epidemiologic studies of achalasia is challenging. Globally reported incidence values range widely from 0.03 to 1.63 per 100,000 persons per year [1] [2] [3] [4] [5] [6] [7] and prevalence from 1.8 to 12.6 per 100,000 persons per year 2, 3, 7, 8 suggesting wide disparities in either the incidence of the disease or in its detection. Most existing estimates were based on achalasia diagnoses using conventional manometry or, in older studies, barium esophagram. 1 The limited available data from the United States were based on small reviews of hospital discharge data 4 or physician surveys. 5 More recently, high-resolution manometry (HRM) has been adopted as a technologic advance that likely improves the standardization of motility testing and improves its diagnostic sensitivity for achalasia. 9, 10 In parallel with the adoption of HRM, an objective classification scheme for esophageal motility disorders (the Chicago Classification) was developed using HRM-specific metrics that likely also enhanced the recognition of achalasia. 11 Our medical center has been a leader in the management of esophageal motility disorders for decades, attracting referrals from within the Chicago metropolitan area and regionally. We were also early adopters of HRM technology, using this for all of our clinical studies since 2005 and leading the global effort in the development and maturation of the Chicago Classification (version 3.0). 11 Based on this experience, during which we encountered hundreds of patients with achalasia annually, we hypothesized that achalasia was more common than suggested by existing epidemiologic studies. However, getting an accurate estimate of achalasia incidence requires not only a population-based dataset, but also uniform access to high-quality diagnostics within that population-based dataset, and that combination is very challenging within the US health care matrix. To our knowledge, no such dataset exists. In our case, some compromise needed to be made in defining a populationbased sample to circumvent referral bias. Hence, we decided to analyze the epidemiology of achalasia in Chicago assuming that we encountered every incident case at our institution, thereby allowing us to use the city demographics as a population-based denominator. We hypothesized that, although this assumption is not true, it will only result in an underestimation of achalasia incidence and prevalence and that the magnitude of that underestimation will increase with increasing geographic separation from our institution. Hence, the aim of this study was to estimate the incidence and prevalence of achalasia between 2004 and 2014 in the entire adult population of Chicago, and in the neighborhoods surrounding Northwestern Memorial Hospital (NMH).
Methods

Cases and Study Design
We conducted a retrospective longitudinal study of achalasia cases using the Northwestern Medicine Enterprise Data Warehouse (NMEDW), a comprehensive and integrated database of Northwestern Medicine electronic health records (EHRs). We collected patient demographics and address histories for all patients ages 18 years with an encounter diagnosis of achalasia and/ or idiopathic esophagogastric junction outflow obstruction (EGJOO) between 2004 and 2014. Case definition/ inclusion criteria included an encounter diagnosis based on the final impression of the treating physician of idiopathic achalasia and/or idiopathic EGJOO and not diagnosed as such in the prior 2 years and residence within the city of Chicago. Because EGJOO is heterogeneous, we included only idiopathic cases that were managed as achalasia and assumed to be instances of early or incompletely expressed achalasia. 11 Dates of diagnosis were determined and diagnoses were confirmed by manual review of diagnostic test reports (ie, esophageal manometry and barium esophagram) and physicians' notes performed by 1 investigator (S.S.). Subjects were excluded for incorrect coding of achalasia; absence of EHRs available for review; or secondary achalasia, such as that attributable to prior fundoplication or mechanical obstruction. The Northwestern University Institutional Review Board approved the study protocol (#STU00200613).
Northwestern Medicine Enterprise Data Warehouse Search Procedure/Zip Codes Data Extraction
The NMEDW was queried for achalasia cases based on the case inclusion criteria mentioned previously using the International Classification of Diseases-Ninth Revision-Clinical Modification code 530.0 for achalasia. The EGJOO cases were identified in NMEDW by performing a free text search of the manometry report notes, because there was no International Classification of Diseases-Ninth Revision code for this entity. This list was crosschecked with recorded patient address histories to determine which patients also lived in Chicago for at least some time during the study period. Cases were included in prevalence rate calculations during all years that the patient had an active Chicago address on file. If individuals were first diagnosed with achalasia during a year they lived in Chicago, they were also included in the incidence calculations.
We hypothesized that our capture rate for incident achalasia cases would be greatest in the neighborhoods closest to NMH. Therefore, in addition to calculating the rates for the entire city of Chicago we grouped 13 zip codes surrounding NMH (60601, 60602, 60603, 60604, 60605, 60606, 60610, 60611, 60613, 60614, 60654, 60657, and 60661) and analyzed that data separately because their residents would be more likely to visit NMH than another institution (this is referred to as NMH Neighborhood throughout this article). Figure 1 illustrates a map of the city of Chicago highlighting the NMH Neighborhood area and the major academic and community medical centers in the city. Data for the entire city also included that of the NMH Neighborhood.
Incidence and Prevalence Calculation
Assuming that the population remained fairly stable during the study period, we used the US 2000 Census Bureau population data as the denominator for incidence and prevalence rates resident cases within each year by the total population, and prevalence rates were calculated by dividing the number of total resident cases within each year by the total population. Cases with unknown dates of diagnosis were mostly diagnosed before 2000 and were included in prevalence, but not incidence, calculations. Rates are reported per 100,000 persons per year.
Statistics
Total annual and gender-based incidence and prevalence rates were calculated along with their 95% confidence intervals, as estimated using the Clopper-Pearson interval method. R version 3.2.0 (R Foundation for Statistical Computing, Vienna, Austria) was used for the statistical analysis.
Results
The initial NMEDW query identified 545 potential cases (achalasia and EGJOO combined) that had addresses within Chicago during the study period; additional review excluded 166 cases for various reasons as follows, mostly for incorrect coding: gastroesophageal reflux disease (49), secondary achalasia (previous surgery and/or mechanical obstruction) (20) , oropharyngeal dysphagia (13), eosinophilic esophagitis (12), aperistalsis in scleroderma (8) , aperistalsis (4), jackhammer esophagus (3), hypertensive peristalsis-nutcracker esophagus (1), esophageal varices (1), esophageal diverticulum (1), rumination syndrome (1), functional dyspepsia (2), peptic ulcer disease (1), gastric outlet obstruction (1), gastroparesis (4), eosinophilic gastroenteritis (1), fake test patient (2), nausea secondary to constipation (1), no objective esophageal disorder identified (34), incomplete work-up (1), no EHRs available to review (5), and diagnosed outside the study period (1) . A total of 379 cases (50.9% female) met full inclusion criteria (11 cases had unknown dates of diagnosis), of which 246 (mean age at diagnosis, 56 years; range, 20-95; 50.4% female) were incident cases. Among the total and incident cases in the city, 23 and 21 patients with EGJOO were included, respectively. Within the NMH Neighborhood, 132 cases (41.7% female) met full inclusion criteria (4 cases had unknown dates of diagnosis), of which 89 (mean age at diagnosis, 56 years; range, 22-89; 38.2% females) were incident cases. Among the total and incident cases in the NMH Neighborhood, 8 and 7 patients with EGJOO were included, respectively. Figure 2 illustrates the age distribution of incident cases in Chicago and the NMH Neighborhood during the entire study period.
Incidence
The incidence of achalasia for Chicago ranged from 0.77 to 1.35 per 100,000 persons per year and for the NMH Neighborhood from 1.41 to 4.60 per 100,000 persons per year. The mean incidence over the 11-year period for Chicago was 1.07 per 100,000 and for the NMH Neighborhood was 2.92 per 100,000. When we calculated incidence by gender for Chicago, the rates for females ranged from 0.65 to 1.50 per 100,000 (mean, 1.05 per 100,000) and for males from 0.60 to 1.59 per 100,000 (mean, 1.10 per 100,000). For the NMH Neighborhood, the rates for females ranged from 0.68 to 4.10 per 100,000 (mean, 2.15 per 100,000) and for males from 0.73 to 7.34 per 100,000 (mean, 3.73 per 100,000). The overall incidence varied from year to year but remained relatively stable over the study period. Figure 3 represents the yearly total and gender-based incidence with the 95% confidence intervals for Chicago and the NMH Neighborhood. Male incidence was noticeably greater in the NMH Neighborhood beginning in 2010.
Prevalence
Achalasia prevalence for Chicago ranged from 4.68 to 14.42 per 100,000 persons per year and for the NMH Neighborhood from 15.64 to 32.58 per 100,000 persons per year. When we calculated prevalence by gender for Chicago, the rates for females ranged from 4.56 to 13.95 per 100,000 and for males from 4.81 to 14.91 per 100,000. For the NMH Neighborhood, the rates for females ranged from 11.50 to 28.05 per 100,000 and for males from 19.94 to 37.45 per 100,000. The overall prevalence increased throughout the study period. Figure 4 represents the yearly total and gender-based prevalence with the 95% confidence intervals for Chicago and the NMH Neighborhood. Male prevalence was noticeably higher throughout the study period.
Discussion
The aim of this study was to reconcile the seemingly low epidemiologic estimates of achalasia incidence and prevalence with our recent clinical experience at a major academic referral center for motility disorders in central Chicago suggesting it to be more common. We analyzed data from 2004 to 2014, a time span during which we used HRM and a very consistent state-of-the-art diagnostic approach to achalasia. We approximated a population-based sample by using US census data of Chicago demographics and assuming that we encountered every incident achalasia case in the city. Recognizing that the validity of that assumption was greatest in our immediate neighborhood and less so in the city at large, we calculated our estimates of incidence and prevalence both for the NMH Neighborhood comprised of approximately 275,000 adults and for the city as a whole, comprised of about 2.1 million adults. Consistent with our hypothesis, our major finding was that the incidence of achalasia in the NMH Neighborhood was relatively stable ranging from 1.41 to 4.60 per 100,000 persons per year over this 11-year span, averaging 2.92 per 100,000 persons per year. These estimates are about twice the upper limit of previous estimates. Even for the city at large our estimates of achalasia incidence ranged from 0.77 to 1.35 per 100,000 persons per year averaging 1.07 per 100,000 persons per year, which is consistent with previous estimates. As for prevalence data, we found this to be consistently greater than previous estimates and to progressively increase throughout the study period, peaking at 32.58 per 100,000 persons per year in the NMH Neighborhood, almost 3 times the upper limit of previous estimates. Table 1 summarizes previous studies of achalasia epidemiology globally.
Although substantially greater than previously reported, our achalasia incidence estimate for the NMH Neighborhood was still likely an underestimate because it assumed that every incident achalasia case in the NMH Neighborhood was diagnosed, and that every incident case was managed at NMH. Clearly, neither of these assumptions was true. Achalasia is not a fatal disease and we simply do not know what fraction of cases goes undetected. A very large population-based HRM study is required to really answer this question. As for the second assumption, although we do command a large market share, the reality of competing insurance networks, the uninsured, and the underinsured make it a virtual certainty that a substantial number of cases are managed elsewhere. However, both of these sources of error result in underestimating the incidence of achalasia. When the city at large is considered, the magnitude of both of these sources of error increases substantially, but even then the incidence value that we report (1.07 per 100,000) is in line with the upper limits as detailed in Table 1 .
Previous reports (Table 1) have estimated the upper limits of achalasia prevalence as approximately 15 times greater than the incidence. Hence, it is difficult to reconcile the progressive increase in prevalence evident in Figure 4 , even as the value now triples that of previous estimates. One could argue that the rising prevalence over time is likely caused by the chronic, low-mortality nature of achalasia 12 leading us to simply accumulate cases over time. However, it still should plateau at some point, albeit at a value substantially greater than the incidence value. Given that the mean age of diagnosis in the NMH Neighborhood was 56 years of age and assuming an average life expectancy at age of 56 in the United States is 26.2 years, 13 one would anticipate that achalasia prevalence would stabilize at a value about 26 times the incidence or, in this case, at 76 per 100,000 population, approaching 0.1%. Evidently, even after 11 years, we can anticipate that the trend of increasing prevalence will continue for many years to come. Other possible explanations for rising prevalence are that patients tend to reside in or move to areas close to esophageal centers of excellence such as ours or, more likely, that the increased awareness of the disease and advancement in diagnostics has resulted in increased recognition of the disease.
Previous epidemiologic studies of achalasia were based on diagnoses made with conventional manometry. The current study is the first report of achalasia epidemiology in the United States conducted uniformly using HRM in the diagnostic evaluation. HRM, which has been used at NMH since 2004 and has been uniformly used since 2005, offers improved characterization of esophageal contractility, particularly lower esophageal sphincter relaxation, an essential diagnostic criterion for achalasia. The integrated relaxation pressure metric, a cornerstone of Chicago Classification criteria, offers improved sensitivity and specificity to diagnose achalasia over conventional manometry. 10 This may well have contributed to our central finding that achalasia is more common than previously thought. Ultimately, it seems that HRM may detect more patients with achalasia than conventional manometry, a premise also supported by a recent randomized European study. 14 As with any retrospective or population-based epidemiologic study of rare diseases, our study is subject to and limited by potential biases, such as referral bias and difference in access to healthcare resources. Furthermore, our prevalence data may be an overestimate because of referral bias to our center and we may have underestimated emigration from the population if patients did not update address information in our EHRs. Other potential limitations are accuracy of diagnostic and address information recorded (a general problem with administrative databases). 15 Coding errors may have caused our search strategy to fail to identify and include some patients. However, a strength of our study is that we rigorously reviewed all patient charts to only include patients that had an achalasia diagnosis confirmed. Furthermore, we took the conservative approach of excluding patients with insufficient records for review, even though they may actually have had achalasia.
In conclusion, our study indicates that the incidence of achalasia in central Chicago is at least twice the upper limit of previous estimates from around the world and the prevalence is at least 3 times greater. We speculate that the higher rates are caused by recent advancements in diagnostics (HRM), in diagnostic criteria (the Chicago Classification), and enhanced awareness of the disease. Additional studies are needed to determine the generalizability of these data to other regions.
